Zum Inhalt springenZur Suche springen

Work-In-Progress Seminar

Work-In-Progress Seminar

For the intensive exchange of information on the current state of the projects, all doctoral students will present and discuss the research results during the work-in-progress seminar in the presence of their supervisor team.

The work-in-progress seminar is combined with the scientific colloquium.

Summer Semester 2022

The colloquia will take place in lecture hall 6A starting at 4:30 pm.

Date Speakers Title
25.04.22 Prof. Dr. Nadine Ziemert, University Hospital Tübingen,Translational Natural Product Genomics A Genome Mining Pipeline for antibiotic discovery in bacteria
02.05.22 Progress Reports  
  Larissa Hinz Modular synthesis of Indolophenazine-Derivatives as active agents against Toxoplasma gondii
  Stefan Höfmann Development of novel 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway inhibitors
09.05.22 Prof. Dr. Thomas Efferth, Institute of Pharmaceutical and Biomedical Sciences, Johannes-von-Gutenberg-University, Mainz tba  
16.05.22 Progress Reports  
  Lars Seiffert tba
  Julian Schliehe-Diecks tba
23.05.22 Dr. Maximilian Barth, Institute of Pharmaceutical and Medicinal Chemistry, HHU Drug Metabolism and Pharmacokinetics in Drug Discovery and the DMPK Service Unit at IPMC
30.05.22 Progress Reports  
  Korana Mudrovcic tba
  Annabelle Friedrich tba
13.06.22 Prof. Dr. Christian Ducho, Pharmazeutische und Medizinische Chemie, Saarland University Medicinal Chemistry with Naturally Occurring Nucleoside Antibiotics
20.06.22 Progress Reports  
  Talea Knak tba
  Ilka Hinxlage tba
27.06.22 Prof. Dr. Nicole Teusch, Pharmaceutical Biology and Biotechnology, HHU tba
04.07.22 Progress Reports  
  Mariam Dubiel tba
  Julia Gottstein tba

Winter Semester 2021/2022

The colloquia will start at 4:30 pm.

Date Speakers Title
04.10.21 Dr. Christopher Stroh, Director Translational and Biomarker Research, Merck Group A precision medicine approach to target the receptor tyrosine kinase MET in cancer
18.10.21 Information event on the Feodor Lynen Fellowship of the Alexander von Humboldt Foundation  
25.10.21 Prof. Dr. Heike Brötz-Oesterhelt, Interfaculty Institute of Microbiology and Infection Medicine, Microbial Bioactive Compounds, University Tübingen Antibiotic Modes of Action - Technologies & Research Stories
08.11.21 Prof. Dr. Andreas Reichert, Institute of Biochemistry and Molecular Biology I, Heinrich-Heine-University Düsseldorf Structure-function relations of mitochondria
15.11.21 Progress Reports  
  Julia Gottstein Lantibiotic resistance in human pathogens
  Mariam Dubiel Histamine H4 receptors in cancer - perspectives as potential molecular target
29.11.21 Progress Reports (lecture hall 5H)  
  Emmanuel Adeniyi Characterization of molecular mechanisms underlying antimycobacterial activity of callyaerins
  Xiaoli Yang Beauvericin exhibits immunostimulatory effects on conventional dendritic cells via activating the TLR4 signaling pathwaysistant tumors and bacterial pathogens
06.12.21 Dr. Jan Bülle, Kutzenberger Wolff & Partner, Partner, Dipl. Chem., Patentanwalt, European Patent & Trademark Attorney Brief Introduction to the Patent System
13.12.21 Progress Reports (lecture hall 5H)  
  Moritz Klischan Biaryl-based natural products as structural motif for pharmaceutically relevant compounds
  Lena Berning Characterization of autophagy-modulating natural products and derivatives for the elimination of therapy-resistant tumor cells
10.01.22 Prof. Dr. Alice McHardy, Computational Biology of Infection Research, Helmholtz Centre for Infection Research Critical Assessment of Metagenome Interpretation - the second round of challenges
17.01.22 Progress Reports (lecture hall 5H)  
  Marlena Sekeres Modulation of the DNA damage response (DDR) by natural compounds (NC) to widen the therapeutic window of anticancer drugs
  Pablo Cea Structure based drug design against Nisin resistance systems
24.01.22 Prof. Dr. Robin Teufel, Pharmaceutical Biology Division, Department of Pharmaceutical Sciences, University of Basel Insights into the biosynthesis of bioactive bacterial tropone and polyketide natural products
31.01.22 Progress Reports (via Webex)  
  Fabian Fischer Development of HDAC-inhibitors and HDAC-PROTACs
  Flaminia Mazzone Identification and characterization of new natural products with antimicrobial activity against Toxoplasma gondii

Summer Semester 2021

The colloquia will take place as online meetings starting at 4:30 pm. The invitation link will be send by email.

Date Speakers Title
19.04.21 Progress Reports  
  Flaminia Mazzone Identification and characterization of new natural products with anti-microbial activity against Apicomplexa and multiresistant gram-negative rods (4MRGN)
  Laura Mayer Diversity-oriented synthesis of diaryl substituted heterocycles via sequential palladium catalysis
26.04.21 Progress Reports  
  Pablo Cea Structural studies of nisin resistance and immunity systems
  Lars Seiffert Synthesis of small-molecule inhibitors of nisin resistance protein
10.05.21 Progress Reports  
  Julian Schliehe-Diecks Characterization of synergy and resistance traits of HSP90 and HDAC inhibitors in leukemic cell lines
  Fabian Fischer Development of chemosensitizing HDAC-Inhibitors and HDAC-PROTACs
17.05.21 Dr. Christine Beemelmanns, Junior Research Group Leader Chemical Biology of Microbe-Host Interactions, Leibniz Institute for Natural Product Research and Infection Biology e.V., Hans-Knöll-Institute (HKI) Novel Secondary Metabolites from Microbial Interactions
31.05.21 Prof. Dr. Dominic Hoepfner, Director Genomic Sciences, Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research How to catch a target: genetic fishing expeditions with natural products
07.06.21 Progress Reports  
  Korana Mudrovcic Exploration of Strategies to Disrupt ULK1 Protein Complex and Chlorflavonin Optimization
  Annabelle Friedrich Targeting protein-protein interactions within the autophagy-inducing ULK1 complex for cancer therapy
14.06.21 Dr. Bert Klebl, Managing Director and Chief Scientific Officer of Lead Discovery Center GmbH, Dortmund, Germany Pandemic Prepardness – a Pathoblocker Concept to Inhibit S. aureus Induced Infections
21.06.21 Progress Reports  
  Talea Knak Structural optimization of Chlorflavonin – a natural product with antimycobacterial activity
  Ilka Hinxlage Identification of Novel Apoptotic Signaling Pathways for the Elimination of Therapy-Resistant Tumors
28.06.21 Dr. Elke Röhrdanz, Head of the Unit Reproductive and Genetic Toxicology, BfArM (Federal Institute for Drugs and Medical Devices) Non-clinical Drug Development
05.07.21 cancelled  
12.07.21 Prof. Dr. Zoe Waibler, Paul-​Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel Batch testing and batch release of immunological biomedicines in Germany